Crescent Biopharma (FRA:C68) Other Stockholders Equity: €0.00 Mil (As of Mar. 2026)


FRA:C68 Crescent Biopharma Inc FRA:C68
18 GF Score
Price €14.60
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Other Stockholders Equity?

Crescent Biopharma FRA:C68 18 Other Stockholders Equity is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:C68 with a GF Score™ of 18/100. The stock has 2 warning signs investors should review.

Crescent Biopharma's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €0.00 Mil.

Crescent Biopharma's quarterly Other Stockholders Equity stayed the same from Sep. 2025 (€0.00 Mil) to Dec. 2025 (€0.00 Mil) but then increased from Dec. 2025 (€0.00 Mil) to Mar. 2026 (€0.00 Mil).

Crescent Biopharma's annual Other Stockholders Equity stayed the same from . 20 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) but then increased from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

Crescent Biopharma Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Other Stockholders Equity Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Other Stockholders Equity
0.00 0.00

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
FRA:C68
18GF Score
Crescent Biopharma Inc FRA:C68
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0.00 Mil mean?
Crescent Biopharma (FRA:C68) has a Other Stockholders Equity of €0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Crescent Biopharma and its competitors.
Is Crescent Biopharma's Other Stockholders Equity too high?
Crescent Biopharma's current Other Stockholders Equity is €0.00 Mil. Overall, Crescent Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Other Stockholders Equity compare to KYTX and ZURA?
Crescent Biopharma's Other Stockholders Equity of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current Other Stockholders Equity is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current Other Stockholders Equity of €0.00 Mil. The current Other Stockholders Equity is €0.00 Mil. Crescent Biopharma's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current Other Stockholders Equity is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges CBIO:USA
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
18GF Score

Get the complete analysis for FRA:C68

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.60
Price